Get the Stockscreener App
26.75
2.37%
0.62
After Hours:
26.44
-0.31
-1.16%
Zai Lab Limited Adr stock is traded at $26.75, with a volume of 724.33K.
It is up +2.37% in the last 24 hours and down -20.74% over the past month.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
See More
Previous Close:
$26.13
Open:
$26.94
24h Volume:
724.33K
Relative Volume:
1.03
Market Cap:
$2.99B
Revenue:
$418.33M
Net Income/Loss:
$-252.07M
P/E Ratio:
-11.15
EPS:
-2.4
Net Cash Flow:
$-238.84M
1W Performance:
+1.56%
1M Performance:
-20.74%
6M Performance:
-14.21%
1Y Performance:
-12.18%
1-Day Range:
$26.46
$27.25
1-Week Range:
$25.13
$27.25
52-Week Range:
$23.82
$44.34
Zai Lab Limited Adr Stock (ZLAB) Company Profile
Name
Zai Lab Limited Adr
Sector
Industry
Phone
862161632588
Address
4560 JINKE ROAD, SHANGHAI
Compare ZLAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZLAB
Zai Lab Limited Adr
|
26.75 | 2.91B | 418.33M | -252.07M | -238.84M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Zai Lab Limited Adr Stock (ZLAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Resumed | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-14-23 | Initiated | Morgan Stanley | Overweight |
| Aug-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-21-22 | Initiated | Macquarie | Outperform |
| Oct-12-21 | Initiated | Bernstein | Mkt Perform |
| Apr-28-20 | Initiated | Goldman | Buy |
| Apr-15-20 | Initiated | Guggenheim | Buy |
| Jul-12-19 | Initiated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
| Jan-29-19 | Initiated | Credit Suisse | Outperform |
| Nov-21-18 | Initiated | Jefferies | Buy |
| Jun-21-18 | Resumed | Leerink Partners | Outperform |
| Feb-14-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Initiated | JP Morgan | Neutral |
| Oct-16-17 | Initiated | Leerink Partners | Outperform |
View All
Zai Lab Limited Adr Stock (ZLAB) Latest News
Keeping an Eye on Nine Energy Service Inc (NINE) After Insider Trading Activity - knoxdaily.com
Zai Lab (NasdaqGM:ZLAB): Evaluating Valuation Following Promising Trial Results and Phase 3 Progress - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zai Lab (ZLAB) to Release Quarterly Earnings on Thursday - MarketBeat
Zai Lab Announces Participation in Investor Conferences in November and December 2025 - The Globe and Mail
Zai Lab Announces Participation in Investor Conferences in September 2025 - FinancialContent
Zai Lab (NASDAQ:ZLAB) Stock Price Down 4.6%Time to Sell? - MarketBeat
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study - Business Wire
Q3 Earnings Estimate for Zai Lab Issued By Leerink Partnrs - MarketBeat
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last? - MSN
Zai Lab Secures RMB300 Million Debt Facility - The Globe and Mail
[8-K] Zai Lab Ltd Reports Material Event | ZLAB SEC FilingForm 8-K - Stock Titan
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 - The Globe and Mail
Zai Lab (NASDAQ:ZLAB) Trading Down 6.2%Here's What Happened - MarketBeat
Late‑breaking Phase 1 data for Zoci: Zai Lab to present DLL3‑targeted ADC results at AACR Oct 24, 2025 - Stock Titan
Operating cash flow per share of Zai Lab Ltd. Sponsored ADR – BER:1ZL - TradingView
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference - Business Wire
Trip.com Group LimitedAmerican Depositary Shares (NQ: - FinancialContent
Is Zai Lab's Valuation Justified as Revenue Growth Lags the Biotech Industry (ZLAB)? - Sahm
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ETFs Investing in Zai Lab Ltd. Sponsored ADR Stocks - TradingView
Zai Lab Limited Announces Equity Incentive Grants to Employees - MSN
Zai Lab (NASDAQ:ZLAB) Shares Gap UpStill a Buy? - MarketBeat
Zai Lab Limited Depositary Receipt Stock Analysis and ForecastStochastic Oscillator Alerts & High Profit Trading Signals - Early Times
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Zai Lab (ZLAB) - The Globe and Mail
How robust is Anheuser Busch Inbev SA Sponsored ADR stock financial position2025 Volume Leaders & Free High Return Stock Watch Alerts - newser.com
Zai Lab Limited Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for DetailsZLAB - ACCESS Newswire
Acadian Asset Management LLC Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Levi & Korsinsky Reminds Shareholders of an Investigation into Zai Lab Limited (ZLAB) Regarding Potential Securities Fraud Allegations - ACCESS Newswire
Lost Money on Zai Lab Limited (ZLAB)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Consensus Price Target from Analysts - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Zai Lab Limited (ZLAB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Insider Buying: Zai Lab (NASDAQ:ZLAB) Insider Purchases 10,000 Shares of Stock - MarketBeat
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages - Defense World
Woodline Partners LP Sells 558,781 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab (NASDAQ:ZLAB) Shares Gap DownTime to Sell? - MarketBeat
Zai Lab Limited ADR (NASDAQ: ZLAB) Is Up 14.37% – Is It Capable Of A Rally? - stocksregister.com
FY2026 EPS Estimates for Zai Lab Reduced by Leerink Partnrs - MarketBeat
Market Sentiment Around Loss-Making Zai Lab Limited (NASDAQ:ZLAB) - 富途牛牛
Raymond James Financial Inc. Boosts Holdings in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Cubist Systematic Strategies LLC Increases Stake in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Benzinga
Zai Lab under pressure over clinical results and rival drugs - thebambooworks.com
Why Zai Lab (ZLAB) Is Down 5.5% After Diminished Final Results for Bemarituzumab in Gastric Cancer - Sahm
Zai Lab FY2026 EPS Forecast Lowered by Leerink Partnrs - Defense World
Canada Pension Plan Investment Board Buys New Shares in Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
MPM Bioimpact LLC Acquires 33,659 Shares of Zai Lab Limited Unsponsored ADR $ZLAB - MarketBeat
Zai Lab Limited Adr Stock (ZLAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):